Skip to main content
. 2021 Apr 12;5(7):2003–2011. doi: 10.1182/bloodadvances.2020002701

Figure 3.

Figure 3.

Outcomes in recipients of KIR3DL1-Weak Inhibiting compared with KIR3DL1-Strong Inhibiting or KIR3DL1- Noninteracting donor recipients in patients with AML. OS (A), cumulative incidence of relapse (B), cumulative incidence of NRM (C), and cumulative incidence of acute GVHD (D).